India: Developing Biosimilars In India: Prescriptions And Problems

Last Updated: 6 November 2014
Article by Priya Anuragini

In India, access to health care facilities is still limited to a very small percentage of population owing mostly to unavailability of affordable drugs and treatment. Surprisingly, this predicament has persisted despite the presence of strong and competent generic pharmaceutical industry which hitherto has been fully supported by both government policies and statutory framework in its endeavour to provide drugs as cheaply as possible. As India looks for newer avenues to meet the healthcare needs of its huge 1.2 billion population "Biosimilars" or "Similar Biologics" represent significant potential.

What exactly are Biosimilars?

"Biosimilars" are similar versions of innovator pharmaceutical product, though not their generic equivalents, which are marketed after the expiration of the patent. As an enormous no. of pharmaceutical patents are expiring in the coming years, biosimilar industry is sure to grow and its capability to produce affordable biotech medicines would further expand. And to ensure optimum development and growth of the market for biosimilars in India, Indian government has already issued "Guidelines on Similar Biologics: Regulatory requirements for market authorization in India" in the year 2012 which lays down specific standards for development and evaluation of similar biologics in India. These guidelines seek to ensure comparability of safety, efficacy and quality between the innovator biologic product and the biosimilar. Since biosimilar products are not identically similar to the reference innovator product, any variation needs to be assessed in detail to ensure that there is no therapeutic consequence for the patient. This essentially means that biosimilar developers do not only have to perform clinical trials on the newly developed biosimilar drug but also on the original product and compare the data to ensure efficacy and safety. The determination that the biosimilar product is similar to the original biologic in terms of structural characteristics, safety, efficacy and quality can only be made after careful scrutiny of analytical, clinical and non-clinical data. Accordingly, biosimilars require a comprehensive evaluation before they can be safely marketed and that is sought to be achieved by the above mentioned guidelines which establish appropriate regulatory pathways to ensure cost effective and safe production of biosimilars in India.

Before Biosimilars can be marketed- Crossing the regulatory threshold

All the biosimilars whether manufactured in India or imported into the country have to follow a multi-step procedure to get marketing authorization in India. The regulatory bodies responsible for approval of 'similar biologics' in India are the: Department of Biotechnology (DBT) under the Ministry of Science and Technology through its Review Committee on Genetic Manipulation (RCGM) and the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare.

The starting point of the regulatory framework enunciates that a similar biologic can be developed in India only if the reference biologic chosen is a licensed innovator product in India. If the reference biologic is not a licensed or marketed innovator product in India then it should have been licensed and marketed for minimum of 4 years post approval in innovator's jurisdiction having well established regulatory framework. Only when this fundamental criterion is fulfilled the multi-step approval process can be initiated.

In the first step of approval, applicant is permitted to conduct studies with the reference biologic so as to generate information regarding manufacturing processes and product characterization. Once the applicant generates the above information, it is submitted along with basic clinical information and preclinical study protocols to the RCGM. In the second step applicant receives the approval to conduct pre- clinical trials which again requires a no. of studies to be made. After the successful evaluation of preclinical study reports, in the third step approval for clinical trials is given. Once all the clinical studies have been successfully completed, in the fourth step applicant can submit an application for market authorization to DGCI (Drug Controller General of India). Once the applicant receives marketing authorization, the similar biologic can be sold in India. Once such marketing authorization is received, the Applicant is required to submit a post-marketing risk management plan.

Important lessons from Roche-Biocon Lawsuit

As is clearly evident the approval process required to develop similar biologics in India stipulates compliance with a long prescribed procedure and would essentially require a significant period of time. Interestingly in one of the recent pharmaceutical lawsuits before Delhi High Court wherein Roche sued Indian pharmaceutical company Biocon and US based global generic Mylan for launching first biosimilar version of its original cancer drug "Herceptin" in India, one of the major contentions of Roche was that launch of "CANMAB" which was said to be biosimilar version of Roche's Herceptin was not in accordance with the guidelines prescribed for similar biologics. After all, what the guidelines prescribe is a long process. However drug was approved by DGCI in considerably short period of time. Moreover there was no public record to show that clinical trials were actually conducted before the drug was approved. Considering that the procedure for approval is multi –step requiring a lot of time, approval for the drug could not have been granted legally in such short span of time by the Drug Controller, Roche claimed. And in absence of compliance with due procedure for approval and non-conduct of appropriate tests the drug cannot be regarded as a biosimilar version and was being misrepresented as such in order to pass off the drug as being of same quality and reputation as Roche's Herceptin . Delhi High Court, accordingly restrained Biocon and Mylan from launching CANMAB without requisite approvals emphasizing the importance of following the prescribed procedure before a biosimilar drug can be sold in the market.

Concerns of Generic manufacturers

At this juncture, India certainly needs cost effective production of biosimilars in order to effectively address its health concerns and detailed and structured guidelines by the Government in this direction are indeed welcome. However, the high threshold of regulatory guidelines coupled with technical requirements and the risk of patent infringement litigation acts as a major deterrent for the generic manufacturers who want express commitment from the government that once they invest in something as complex as biosimilars, they would be allowed to launch it. Many of them have even suggested that a compulsory license be granted prior to development of biosimilars. In view of international obligations this may not always be possible and it's important for the government to alleviate the concerns of the biosimilar developers without comprising on the regulatory compliance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
S.S. Rana & Co. Advocates
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
S.S. Rana & Co. Advocates
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions